TScan Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
142
- Stock Symbol
-
TCRX
- Share Price
-
$0.16
- (As of Friday Closing)
TScan Therapeutics General Information
Description
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Contact Information
Website
www.tscan.comCorporate Office
- 830 Winter Street
- Waltham, MA 02451
- United States
Corporate Office
- 830 Winter Street
- Waltham, MA 02451
- United States
TScan Therapeutics Timeline
TScan Therapeutics Stock Performance
As of 13-Nov-2026, TScan Therapeutics’s stock price is $0.16. Its current market cap is $10.9M with 67.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.16 | $0.17 | $0.16 - $1.47 | $10.9M | 67.8M | 749K | -$0.89 |
TScan Therapeutics Financials Summary
As of 30-Sep-2026, TScan Therapeutics has a trailing 12-month revenue of $5.19M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 12,054 | (32,083) | (8,988) | 150,378 |
| Revenue | 5,186 | 10,325 | 2,816 | 21,049 |
| EBITDA | (113,694) | (132,913) | (131,803) | (88,097) |
| Net Income | (115,087) | (129,766) | (127,499) | (89,218) |
| Total Assets | 141,401 | 228,789 | 371,118 | 272,149 |
| Total Debt | 89,276 | 94,138 | 97,381 | 92,433 |
TScan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TScan Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
TScan Therapeutics Comparisons
Industry
Financing
Details
TScan Therapeutics Competitors (49)
One of TScan Therapeutics’s 49 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| T-Knife Therapeutics | Venture Capital-Backed | Berlin, Germany | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Vyriad | Venture Capital-Backed | Rochester, MN | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
TScan Therapeutics Patents
TScan Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025275148-A1 | Binding proteins recognizing cd45 immunogenic peptides and uses thereof | Pending | 06-Dec-2024 | ||
| WO-2026122679-A1 | Binding proteins recognizing cd45 immunogenic peptides and uses thereof | Pending | 06-Dec-2024 | ||
| AU-2025260022-A1 | Binding proteins recognizing magea4 immunogenic peptides and uses thereof | Pending | 07-Nov-2024 | ||
| WO-2026117350-A2 | Binding proteins recognizing magea4 immunogenic peptides and uses thereof | Pending | 07-Nov-2024 | ||
| WO-2026117350-A3 | Binding proteins recognizing magea4 immunogenic peptides and uses thereof | Pending | 07-Nov-2024 | A61P35/00 |
TScan Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TScan Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TScan Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
TScan Therapeutics FAQs
-
When was TScan Therapeutics founded?
TScan Therapeutics was founded in 2018.
-
Where is TScan Therapeutics headquartered?
TScan Therapeutics is headquartered in Waltham, MA.
-
What is the size of TScan Therapeutics?
TScan Therapeutics has 142 total employees.
-
What industry is TScan Therapeutics in?
TScan Therapeutics’s primary industry is Biotechnology.
-
Is TScan Therapeutics a private or public company?
TScan Therapeutics is a Public company.
-
What is TScan Therapeutics’s stock symbol?
The ticker symbol for TScan Therapeutics is TCRX.
-
What is the current stock price of TScan Therapeutics?
As of 13-Nov-2026 the stock price of TScan Therapeutics is $0.16.
-
What is the current market cap of TScan Therapeutics?
The current market capitalization of TScan Therapeutics is $10.9M.
-
What is TScan Therapeutics’s current revenue?
The trailing twelve month revenue for TScan Therapeutics is $5.19M.
-
Who are TScan Therapeutics’s competitors?
Fate Therapeutics, T-Knife Therapeutics, Instil Bio, Vyriad, and Kite Pharma are some of the 49 competitors of TScan Therapeutics.
-
What is TScan Therapeutics’s annual earnings per share (EPS)?
TScan Therapeutics’s EPS for 12 months was -$0.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
